Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (90Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma

Cancer Science

Volumn 96, Issue 12, 2005, Pages 903-910

  Watanabe, Takashi ^a   Terui, Shoji ^a   Itoh, Kuniaki ^c   Terauchi, Takashi ^b   Igarashi, Tadahiko ^c   Usubuchi, Noriko ^c   Nakata, Masanobu ^c   Nawano, Shigeru ^c   Sekiguchi, Naohiro ^a   Kusumoto, Shigeru ^a   Tanimoto, Kazuki ^a   Kobayashi, Yukio ^a   Endo, Keigo ^d   Seriu, Taku ^d   Hayashi, Masaki ^d   Tobinai, Kensei ^a,e  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d GUNMA UNIVERSITY HOSPITAL   (Japan)

^e Nihon Schering KK   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IBRITUMOMAB TIUXETAN; RITUXIMAB;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ANEMIA; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EPISCLERITIS; FEMALE; FOLLICULITIS; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPONATREMIA; INFECTION; JAPAN; LYMPHOCYTOPENIA; MALAISE; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; STOMATITIS; THROMBOCYTOPENIA; TINEA PEDIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOIMMUNOTHERAPY; RECURRENCE; REPRODUCIBILITY OF RESULTS; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 30344451659     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetasy.2005.01.017     Document Type: Article

References (16)

1. Gates VL, Carey JE, Siegel JA et al. Nonmyeloablative iodine-131 anti-B1 radioimmumotherapy as outpatient therapy. J Nucl Med 1998; 39: 1230-6.
2. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002; 20: 3545-57.
3. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-803.
4. Davis TA, White CA, Grillo-López AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851-7.
5. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-63.
6. Witzig TE, Flinn IW, Gordmn LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-9.
7. Non-Hodgkin's Lymphoma Pathological Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-35.
8. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
9. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
10. Tobinai K, Kobayashi Y, Narabayashi M et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998; 9: 527-34.
11. Igarashi T, Kobayashi Y, Ogura M et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002; 13: 928-43.
12. Coursey BM, Calhoun JM, Cessna JT. Radioassays of yttrium-90 used in nuclear medicine. Nucl Med Biol 1993; 20: 693-9.
13. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-53.
14. 90Y-ibritumomab tiuxetan radiommumotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from four clinical trials. J Nucl Med 2003; 44: 465-74.
15. Igarashi T, Ohtsu T, Fujii H et al. Re-treatment of relapsed indolent B-cell lymphoma, with rituximab. Int J Hematol 2001; 73: 213-21.
16. Davis TA, Grillo-López AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-43.